Orion Corporation's royalty income outpaced expectations in January-September, prompting the Finnish drugmaker to raise both its 2026 sales and operating profit outlooks; it expects the trend to continue through year-end.
Orion now estimates net sales of €2,070 million to €2,140 million and operating profit of €730 million to €790 million. Its July outlook put sales at €2,000 million to €2,100 million and operating profit at €650 million to €750 million.
The company reported net sales of €1,890 million in 2025. Its business includes medicines for people and animals, with oncology and pain among its main pharmaceutical research areas.
Orion is scheduled to publish its interim report for January-September on Wednesday, Oct. 28, at about 6 a.m. ET (10:00 UTC).
